Your browser is no longer supported. Please, upgrade your browser.
GHSI Guardion Health Sciences, Inc. daily Stock Chart
GHSI [NASD]
Guardion Health Sciences, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own12.40% Shs Outstand23.10M Perf Week-57.35%
Market Cap6.41M Forward P/E- EPS next Y- Insider Trans- Shs Float10.94M Perf Month-82.88%
Income-6.80M PEG- EPS next Q- Inst Own0.10% Short Float0.22% Perf Quarter-80.47%
Sales1.00M P/S6.41 EPS this Y-72.50% Inst Trans185.19% Short Ratio0.01 Perf Half Y-
Book/sh0.21 P/B1.32 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.10 P/C2.67 EPS next 5Y- ROE- 52W Range0.20 - 4.00 Perf YTD-92.46%
Dividend- P/FCF- EPS past 5Y-50.10% ROI-192.00% 52W High-92.80% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y29.30% Gross Margin58.40% 52W Low42.72% ATR0.23
Employees94 Current Ratio5.40 Sales Q/Q50.00% Oper. Margin- RSI (14)26.58 Volatility23.44% 19.60%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume5.46 Prev Close0.28
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.82M Price0.29
Recom- SMA20-69.24% SMA50-75.93% SMA200-82.39% Volume6,844,301 Change3.86%
Aug-15-19 04:05PM  Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering GlobeNewswire
08:35AM  Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering GlobeNewswire
Aug-13-19 09:00AM  Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering GlobeNewswire -59.66%
Aug-12-19 08:40AM  Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations GlobeNewswire -8.49%
Aug-06-19 07:00AM  Foundation Fighting Blindness selects Guardions VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial GlobeNewswire
Jul-19-19 02:47PM  What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)? Simply Wall St.
Jul-17-19 07:00AM  Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry GlobeNewswire +93.75%
Jun-20-19 07:00AM  Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union GlobeNewswire +7.23%
Jun-04-19 07:00AM  Guardion Launches Second Ocular Health Formula GlaucoCetin GlobeNewswire +24.84%
May-09-19 10:14AM  Guardions Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2 GlobeNewswire
May-07-19 07:00AM  Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma GlobeNewswire
May-01-19 07:00AM  Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China GlobeNewswire +6.36%
Apr-17-19 09:01AM  Results of Lumega-Z Data to be Presented at ARVO GlobeNewswire -12.00%
Apr-11-19 09:18AM  WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services PR Newswire
Apr-09-19 12:20PM  Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering GlobeNewswire -7.04%
Apr-05-19 12:49PM  Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering Business Wire
Guardion Health Sciences, Inc., a specialty health sciences company, develops, formulates, and distributes condition-specific medical foods in the United States and internationally. It operates in two segments, Medical Foods and Vision Testing Diagnostics. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; MapcatSF, a medical device that measures the macular pigment optical density; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Vision Testing Diagnostics segment develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. Its products include VectorVision CSV-1000, an instrument for contrast sensitivity testing; and ESV-3000 ETDRS, a device for early treatment diabetic retinopathy study in visual acuity testing. The company distributes its products through direct sales force, as well as through its guardionhealth.com Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.